Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination

Plain-language summary

This 2024 study found that MOTS-c levels were significantly reduced in both serum and tumor tissues from ovarian cancer patients, and that low MOTS-c expression was associated with poor prognosis. Exogenous MOTS-c inhibited ovarian cancer cell growth in vitro and in vivo by promoting LARS1 degradation through attenuation of USP7-mediated deubiquitination. The findings identify MOTS-c as a novel anti-tumor peptide with mechanistic implications for ovarian cancer research.